Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$6.30 ▼ -0.10
(-1.64%)
MKT CAP: $652.8M • VOL: 770.0K
52W L $5 52W H $10
ROARABLE / RQD
D- • 40/100
PIOTROSKI
2 / 9
AURA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$112.8M | -$96.1M | -$85.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$106.2M | -$86.9M | -$76.4M |
| EBITDA (Normalized) | -$112.4M | -$95.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$84.7M | -$79.8M | -$63.8M |
| Capital Expenditures (CapEx) | $447.0K | $1.3M | — |
| Free Cash Flow (FCF) | -$85.2M | -$81.1M | -$63.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $59.5M | $31.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $136.9M | $152.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AURA.